Financial Data and Key Metrics Changes - The company achieved record full-year revenue of $3.9 million, a 20% increase compared to 2024, with fourth quarter revenue of $1.5 million, representing a 92% increase over the prior year period [3][9] - Gross profit for the fourth quarter was $1 million or 69% of revenue, compared to $0.4 million or 46% of revenue in the prior-year quarter, marking a 188% increase and a 23 percentage point improvement in gross margin [10] - Operating expenses totaled $3.9 million for the fourth quarter of 2025, up from $3.5 million in the prior year quarter, while for the full year, operating expenses totaled $15.2 million, compared to $15.5 million in the prior year period [11][12] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by an increase in surgical procedures across both the Catamaran and SImmetry+ platforms, particularly in the second half of 2025, led by new physician users [3][9] - The company hosted 24 physicians in targeted training sessions for both platforms during the fourth quarter, supporting clinical engagement and adoption [4] Market Data and Key Metrics Changes - The company received FDA 510(k) clearance for the next generation SImmetry+ SI joint fusion system, enhancing its ability to serve a broader range of surgeon preferences and patient anatomies [4][7] - The company expanded its intellectual property portfolio, receiving notices of allowance for multiple applications expected to issue in 2026, bringing its global estate to 29 issued U.S. patents and 31 pending applications [7] Company Strategy and Development Direction - The company is committed to advancing its market position with increased adoption across its expanding portfolio, leveraging regulatory and market momentum to drive broader commercial uptake [8] - The focus is on optimizing the cost structure and scaling operations to extend market reach more efficiently, with plans to accelerate revenue growth and deliver sustained value [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet and exceed expectations in 2026, citing strong adoption momentum and an engaged pipeline [22][28] - The company believes that the fourth quarter and full year of 2025 served as a pivotal inflection point, delivering meaningful progress across key priorities [14] Other Important Information - The company ended the quarter with $3.8 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024, and had no outstanding debt [12] - Subsequent to the quarter end, the company closed a $4.3 million private placement of senior convertible notes to fund commercial expansion and clinical priorities [12][6] Q&A Session Summary Question: What is the outlook for operating expenses in 2026? - Management indicated that the Q4 operating expense rate of $3.9 million is a better baseline moving forward into 2026, with some higher integration costs falling out [16][17] Question: How does the company view revenue growth for 2026? - Management expressed excitement about the adoption momentum and the impact of new product launches, indicating confidence in meeting revenue expectations [21][25] Question: What are the key drivers for revenue growth in 2026? - Management highlighted the multi-product portfolio and the ability to address various patient needs as key drivers for revenue growth, emphasizing commercial expansion and execution [28][27] Question: How is the launch of SImmetry+ impacting access to physicians? - Management noted that the broader portfolio allows for multiple solutions, opening doors to more prospective physicians and medical centers [33][34]

Financial Data and Key Metrics Changes - Curis reported a net income of $19.4 million or $1.23 per share for Q4 2025, compared to a net loss of $9.6 million or $1.25 per share for the same period in 2024, primarily due to a $27.2 million one-time non-cash gain from the sale of Erivedge [10] - For the year ended December 31, 2025, the net loss was $7.6 million or $0.58 per share, a significant improvement from a net loss of $43.4 million or $6.88 per share in 2024 [10] - Research and development expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024, and for the year, they were $28.3 million compared to $38.6 million in 2024 [11] - General and administrative expenses also decreased to $2.9 million in Q4 2025 from $3.4 million in Q4 2024, totaling $14 million for the year compared to $16.8 million in 2024 [11] Business Line Data and Key Metrics Changes - The company is making progress in its Take Aim Lymphoma study for primary CNS lymphoma, with expectations for accelerated submissions to the FDA and EMA [4] - Curis is expanding studies of emavusertib into additional NHL subtypes, particularly focusing on its potential to change the treatment paradigm for CLL patients [5][6] Market Data and Key Metrics Changes - The company is actively enrolling patients in its registrational study for PCNSL, with expectations to complete enrollment within 12-18 months [23] - Initial data from the ongoing AML triplet study showed that five of eight evaluable patients achieved MRD conversion, indicating potential for deeper responses [8][9] Company Strategy and Development Direction - Curis is prioritizing its resources towards NHL studies, particularly PCNSL, while also initiating a proof of concept study in CLL [15] - The company aims to improve treatment outcomes by combining emavusertib with existing therapies to achieve deeper responses and potentially complete remission for patients [6][42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in clinical trials and the potential for significant advancements in 2026, particularly in the registrational study for PCNSL and the proof of concept study in CLL [9] - The company anticipates no meaningful revenue in 2026 due to the cessation of cash flows from Erivedge, but believes it has sufficient cash to fund operations into the second half of 2027 [12][29] Other Important Information - Curis has received initial gross proceeds of $20.2 million from financing in January 2026, with expectations for additional proceeds from warrant exercises [12] Q&A Session Summary Question: How is the company prioritizing trial progress between pivotal PCNSL versus CLL and AML? - Management indicated that resources are being prioritized towards NHL, particularly PCNSL, while CLL is in the early stages of study [14][15] Question: Can you provide updates on enrollment for PCNSL? - Management stated that enrollment is on track, with expectations for full enrollment within 12-18 months [23] Question: Should revenue modeling for 2026 reflect no meaningful revenue? - Management confirmed that there will be no meaningful revenue in 2026, as cash flows from Erivedge have ended [29] Question: What kind of data should be expected at ASH 2026 regarding CLL? - Management indicated that they hope to present meaningful data at ASH, focusing on the potential for deeper responses in patients [39][40]

Eton Pharmaceuticals (NasdaqGM:ETON) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsDavid Krempa - Chief Business OfficerIpek Erdogan-Trinkaus - Chief Commercial OfficerJames Gruber - CFOSean Brynjelsen - CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Research Analyst of HealthcareMadison El-Saadi - Healthcare Research AnalystRamakanth Swayampakula - Managing Director and Senior Equity research AnalystOperatorGood afternoon, and welcome to the Eton Pharmaceuticals f ...

Financial Data and Key Metrics Changes - Curis reported a net income of $19.4 million or $1.23 per share for Q4 2025, compared to a net loss of $9.6 million or $1.25 per share for Q4 2024, primarily due to a $27.2 million one-time non-cash gain from the sale of Erivedge [10] - For the year ended December 31, 2025, Curis reported a net loss of $7.6 million or $0.58 per share, an improvement from a net loss of $43.4 million or $6.88 per share for the same period in 2024 [10] - Research and development expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024, and for the year, they were $28.3 million compared to $38.6 million in 2024 [11] - General and administrative expenses also decreased to $2.9 million in Q4 2025 from $3.4 million in Q4 2024, totaling $14 million for the year compared to $16.8 million in 2024 [11] Business Line Data and Key Metrics Changes - The Take Aim Lymphoma study is progressing well, focusing on primary CNS lymphoma, with expectations for accelerated submissions in the U.S. and Europe [4][9] - Curis is exploring the potential of emavusertib to change treatment paradigms in CLL, aiming to improve upon the current standard of care with BTK inhibitors [5][6] Market Data and Key Metrics Changes - Enrollment in the Take Aim Lymphoma study is on track, with expectations for full enrollment within 12-18 months, potentially leading to data availability in 2027 [23] - The company is prioritizing NHL studies over AML, with a focus on registrational approval for PCNSL [15][16] Company Strategy and Development Direction - Curis aims to change the treatment paradigm for CLL by combining emavusertib with BTK inhibitors, targeting deeper responses and potential complete remission [6][7] - The company is actively engaging with key opinion leaders to expand studies into additional NHL subtypes, indicating a strategic focus on broadening its clinical research [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in clinical trials and the potential for significant advancements in 2026, particularly in the registrational study for PCNSL and the proof of concept study for CLL [9] - The management acknowledged the challenges in patient enrollment for PCNSL but remains confident in the study's trajectory [23] Other Important Information - Curis' cash and cash equivalents as of December 31, 2025, along with expected proceeds from financing, should support operations into the second half of 2027 [12] Q&A Session Summary Question: How is Curis prioritizing trial progress between pivotal PCNSL versus CLL and AML? - Management indicated that resources are being prioritized towards NHL, particularly PCNSL, while CLL is also a focus but at a smaller scale currently [14][15] Question: Can you provide updates on enrollment for PCNSL? - Management confirmed that enrollment is on track, with expectations for full enrollment within 12-18 months [23] Question: Should revenue modeling for 2026 reflect no meaningful revenue? - Management confirmed that there will be no meaningful revenue for 2026, as revenue effectively ended in November 2025 [29] Question: What kind of data should be expected at ASH 2026 for CLL? - Management stated that they hope to present meaningful data at ASH, focusing on the execution of the study and patient enrollment [38][40]

Financial Data and Key Metrics Changes - For Q4 2025, gross revenue was EUR 6.3 million before EUR 700,000 of revenue deferrals, resulting in net revenue of EUR 5.6 million, compared to EUR 1.3 million in Q4 2024, indicating significant growth driven by the U.S. commercial launch [14] - Full year 2025 gross revenue was EUR 11 million before EUR 1 million of revenue deferrals, resulting in net revenue of EUR 10 million, a 122% increase from EUR 4.5 million in 2024 [15] - Gross margin for Q4 2025 was 64%, while the full year gross margin was 63% [14][15] - Total operating loss for Q4 2025 was EUR 18.6 million, relatively stable compared to EUR 18.3 million in Q4 2024, while the full year operating loss increased to EUR 83.5 million from EUR 58.8 million in 2024 [14][15] Business Line Data and Key Metrics Changes - The U.S. commercial launch generated approximately EUR 3.5 million of net revenue in Q4 2025, with $4.5 million of revenue generated from the first full quarter of launch [14][5] - 145 surgeons were trained in 125 high-volume hypoglossal nerve stimulation accounts, with 57 receiving positive Value Analysis Committee approval [5][7] - The company reported consistent reimbursement from both commercial payers (approximately 90% of business) and Medicare (10% of business) during Q4 [9][10] Market Data and Key Metrics Changes - The company closed 2025 with a global gross revenue of EUR 11 million, driven by strong momentum from the U.S. launch [6] - Internationally, growth continued in selected markets, including Germany, the United Kingdom, and the Middle East, with Germany being the first international market to reach profitability [12] Company Strategy and Development Direction - The company aims to continue executing its U.S. commercial launch, having increased its sales force to 40 sales reps covering 200 of the top 400 hypoglossal nerve stimulation accounts [17] - The company is expanding its internal manufacturing footprint to strengthen its competitive position and improve gross margins [17] - The company plans to submit a PMA supplement for the ACCCESS study data by the end of July 2026, potentially leading to U.S. label expansion in early 2027 [24][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the U.S. launch momentum and the opportunity ahead, emphasizing the positive feedback from surgeons and patients regarding Genio's unique features [8][12] - The reimbursement environment is viewed as a normal maturation of an established therapy, with clarity on facility fees expected to support further adoption of Genio [11] - The company anticipates a sequential growth of 25% in U.S. net revenue for the first and second quarters of 2026, driven by continued surgeon training and growing adoption [16] Other Important Information - The company reported a cash position of EUR 48 million as of December 31, 2025, with an expected cash burn rate of approximately EUR 20 million per quarter in the near term [15][29] - The introduction of new C-codes for AGNS by CMS is expected to facilitate billing for traditional Medicare patients, aligning reimbursement for Genio with competitors [10][9] Q&A Session Summary Question: Can you provide an update on the remaining VAC processes and new account activations? - Management confirmed that 120 VAC submissions were made, with 57 approved, and expects the remaining approvals to occur in Q1 2026 [20][21] Question: What is the timeline for the ACCCESS study data and PMA supplement submission? - The 12-month data will be available by the end of June 2026, with analysis taking up to 30 days, leading to a PMA supplement submission by the end of July 2026 [23][24] Question: What is the cash burn rate and guidance for 2026? - The cash burn rate is approximately EUR 20 million per quarter, expected to decrease as revenue traction increases in the U.S. [29] Question: How many implants have been performed, and what is the approach to inventory? - Management clarified that they do not disclose precise implant numbers but indicated that revenue generated in Q4 suggests a significant number of implants were performed [33][34] Question: What are the key drivers for Genio adoption among physicians? - Key drivers include the optionality provided by Genio, its single incision technique, and bilateral stimulation, which resonate well with surgeons [50][51]

Greystone Housing Impact Investors LP (NYSE:GHI) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsJeffrey Neal - Investment AdviserJesse Coury - CFOJonathan Baum - ShareholderKen Rogozinski - Chief Executive OfficerLarry Linden - ShareholderNathaniel Beam - Investment AdviserConference Call ParticipantsChris Muller - Research AnalystMatthew Erdner - Equity Research AnalystOperatorThe Greystone Housing Impact Investors LP conference call. At this time, all participants are in a listen-onl ...

Financial Data and Key Metrics Changes - In Q3, revenues were $329.1 million, down from $335.4 million in the prior year period, reflecting a decrease of approximately 1% [20] - Adjusted operating loss was $24.3 million compared to $20.9 million in the prior year, while adjusted EBITDA was approximately break even compared to $6 million in the prior year [20] - Net loss was $3.5 million compared to a net loss of $1.3 million in the prior year period, with adjusted loss per diluted share increasing to $0.15 from $0.05 [21] Business Line Data and Key Metrics Changes - Children's Book Publishing and Distribution revenues decreased 3% to $197.6 million, with adjusted operating profit improving to $8.9 million from $7.6 million [21] - Book Fairs revenue increased 2% to $113.3 million, driven by higher revenue per fair, while Book Clubs revenues were relatively flat at $14.6 million [22] - Trade Publishing revenues were $69.7 million, down 10% from $77.4 million, reflecting the timing of major releases [23] - Entertainment segment revenues increased by $3.2 million to $16 million, driven by increased episodic deliveries [23] - Education segment revenues were $56.1 million, down 2% from $57.2 million, but adjusted operating loss improved to $5.2 million from $6.9 million [25] Market Data and Key Metrics Changes - International segment revenues were $58.7 million, down from $59.3 million, with a decline primarily driven by publication timing [26] - Demand for English language learning materials continues to expand globally, representing a long-term opportunity [18] Company Strategy and Development Direction - The company completed sale leaseback transactions generating over $400 million in net proceeds, optimizing the balance sheet and enhancing shareholder value [4] - A new $300 million share repurchase authorization was announced, including a $200 million modified Dutch auction tender offer [5] - The company aims to return to growth in the education segment by fiscal 2027, focusing on aligning products with district and school needs [17] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed fiscal 2026 adjusted EBITDA guidance of $146 million-$156 million, despite the impact of sale leaseback transactions [31] - The company expects a return to profitability in Q4, driven by improved performance in Book Fairs and Education segments [32] - Management expressed confidence in achieving a 2% revenue growth target for Q4, supported by positive trends in Book Fairs and education solutions [37][38] Other Important Information - The company established long-term net leverage targets of 2-2.5 times Adjusted EBITDA, balancing balance sheet strength with growth investments [28] - Free cash flow in Q3 was $407 million, reflecting proceeds from sale leaseback transactions [27] Q&A Session Summary Question: Confidence in achieving 2% growth target for Q4 - Management indicated that Book Fairs are a major factor for revenue growth, with positive initial indications [37] Question: Sales pipeline for education solutions - Management expects strong performance in summer reading and other educational products, with improving sales pipeline each quarter [42] Question: Adjusted EBITDA guidance for Q4 - Management expressed confidence in achieving the guidance due to cost mitigation actions and the typical profitability of Q4 [46] Question: Performance of the entertainment segment - Management noted an increase in green lighting activity and expects steady growth in the entertainment market [48] Question: Revenue guidance adjustment for the year - Management clarified that the adjustment was related to trade dynamics and not solely the education segment [60]

Snail (NasdaqCM:SNAL) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsHai Shi - CEO, Chief Strategy Officer, and Chairman of the BoardHeidy Chow - CFOPeter Kang - Senior Vice President and Director of Business Development and OperationsSteven Shinmachi - Investor RelationsNone - TranslatorConference Call ParticipantsMichael Kupinski - Director of Research and Media and Entertainment Senior Research AnalystOperatorThank you for standing by, and welcome to Snail, Inc.'s Q4 and Full Year 2 ...

Financial Data and Key Metrics Changes - The company reported a net loss of $2.6 million or $0.17 per unit for Q4 2025, with cash available for distribution (CAD) at $2.8 million or $0.12 per unit [11] - The book value per unit as of December 31 was $11.70, with the closing unit price on March 18 at $5.87, reflecting a 50% discount to net book value [14][15] Business Line Data and Key Metrics Changes - The company is focused on exiting market rate multifamily joint venture (JV) equity investments while reallocating capital into tax-exempt Mortgage Revenue Bonds, which are expected to provide stable, tax-advantaged earnings [6][9] - The company currently has eight market rate multifamily JV equity investments that are either in lease-up or stabilized, with increasing occupancy noted [7][8] Market Data and Key Metrics Changes - The U.S. municipal bond market saw a recovery in Q4 2025, with the high-grade index showing a 4.3% return for the year [25] - The 10-year MMD was at 2.76% and the 30-year MMD at 4.24% at year-end, with slight increases noted due to inflation uncertainty [26] Company Strategy and Development Direction - The company is repositioning its investment portfolio to focus on tax-exempt Mortgage Revenue Bonds, which are expected to yield stable returns compared to the uneven returns from JV equity investments [5][6] - The strategy aims to increase the proportion of tax-exempt income allocated to unitholders over the long term [7] Management Comments on Operating Environment and Future Outlook - Management acknowledged that it will take time to transition capital from JV equity investments to Mortgage Revenue Bonds, but expects this will enhance recurring earnings in the long run [9][10] - The company is optimistic about the leasing trends as the spring leasing season approaches, indicating a potential recovery in occupancy rates [33][34] Other Important Information - The company reported unrestricted cash and cash equivalents of $39.5 million and approximately $49.2 million available on secured lines of credit as of December 31 [15] - The company has a significant amount of investments maturing in the first half of 2026, which will provide additional liquidity [15] Q&A Session Summary Question: Can you provide specifics on the $7 million losses and how they will be recovered? - The losses were primarily due to four properties completing construction, leading to depreciation and non-capitalized interest expenses. As occupancy increases, these losses are expected to narrow [30][31] Question: What are the leasing trends expected as spring approaches? - Management noted that the March to June period is traditionally strong for leasing, and they are monitoring trends closely with property management firms [33][34] Question: Will the foreclosure of properties result in a loss in Q1? - Initial basis in the foreclosed properties is estimated at $112-$150 million, and management aims to recover the original basis through effective management [39][40] Question: What is the status of the $4.5 million return of capital? - The return of capital relates to refinancing opportunities that allowed for the return of capital to the company, minimizing capital in the deals [44][45] Question: Why has there been little insider buying despite the stock price decline? - Management explained that trading restrictions limit when insiders can buy shares, and there has been no sale activity, indicating confidence in the company [82][85]

Financial Data and Key Metrics Changes - The company achieved record full-year revenue of $3.9 million, a 20% increase compared to 2024, with fourth quarter revenue of $1.5 million, representing a 92% increase over the prior year period [3][9] - Gross profit for the fourth quarter was $1 million or 69% of revenue, compared to $0.4 million or 46% of revenue in the prior-year quarter, marking a 188% increase and a 23 percentage point improvement in gross margin [10] - Operating expenses totaled $3.9 million for the fourth quarter of 2025, up from $3.5 million in the prior year quarter, while for the full year, operating expenses totaled $15.2 million, compared to $15.5 million in the prior year period [11][12] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by an increase in surgical procedures across both the Catamaran and SImmetry+ platforms, particularly in the second half of 2025, led by new physician users [3][9] - The company hosted 24 physicians in targeted training sessions for both platforms during the fourth quarter, supporting clinical engagement and adoption [4] Market Data and Key Metrics Changes - The company received FDA 510(k) clearance for the next generation SImmetry+ SI joint fusion system, enhancing its ability to serve a broader range of surgeon preferences and patient anatomies [4][7] - The company expanded its intellectual property portfolio, receiving notices of allowance for multiple applications expected to issue in 2026, bringing its global estate to 29 issued U.S. patents and 31 pending applications [7] Company Strategy and Development Direction - The company is committed to advancing its market position with increased adoption across its expanding portfolio, leveraging regulatory and market momentum to drive broader commercial uptake [8] - The focus is on optimizing the cost structure and scaling operations to extend market reach more efficiently, with plans to accelerate revenue growth and deliver sustained value [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet and exceed expectations in 2026, citing strong adoption momentum and an engaged pipeline of products [22][28] - The company aims to address various patient needs and physician preferences with a multi-product portfolio, enhancing its competitive position in the market [33] Other Important Information - The company strengthened its financial position through a $2.85 million PIPE financing and a subsequent private placement of senior convertible notes for gross proceeds of $4.3 million, providing additional runway for commercial and clinical priorities [5][12] Q&A Session Summary Question: How representative is the Q4 operating expense rate for 2026? - Management indicated that the Q4 rate of $3.9 million is a better baseline moving forward into 2026, with some higher integration costs falling out in Q4 [17][18] Question: What is the revenue outlook for 2026 relative to the $6 million run rate? - Management expressed excitement about adoption momentum and the impact of new product launches on revenue growth in 2026, although they do not provide specific projections [19][21][25] Question: What are the key drivers for revenue growth in 2026? - Management highlighted the multi-product portfolio and the commercial expansion as key drivers, with a focus on addressing various patient and physician needs [27][28] Question: How is the launch of SImmetry+ impacting access to physicians? - Management noted that the broader portfolio allows for multiple solutions, opening doors to more physicians and medical centers, with positive feedback on the SImmetry+ technology [32][34]